Tivozanib’s Efficacy Behind Checkpoint Inhibitors In Renal Cell Carcinoma Reassured US FDA

Approximately 25% of patients in the TIVO-3 trial had prior treatment with checkpoint inhibitors, but progression-free survival in this subgroup was similar to the overall population, giving the FDA confidence about tivozanib's role in contemporary treatment regimens, Drug Review Profile finds.